



TELESCOPE

INNOVATIONS



FEWER EXPERIMENTS. MORE INSIGHT.

The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, accounting, investment, business, or legal advice, in any way whatsoever. The reader should consult with a lawyer, accountant, and other professionals in respect of contents hereof. Furthermore, the information in no way should be construed or interpreted as, or as a part of, an offering or solicitation of securities. Investors are advised to discuss any trading with a registered securities broker or personal finance professional prior to investing.


This Presentation includes and is based on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Factors that might cause or contribute to such differences include, but are not limited to, economic conditions globally, the impact of competition, political and economic developments in the countries and states in which the Company operates, and regulatory developments domestically and internationally. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "anticipates", "targets", "goals", "projects", "intends", "plans", "believes", "seeks", "estimates", variations of such words, and similar expressions. Important factors that could cause actual results to differ materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for the Company's businesses, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates, and such other factors as may be discussed from time to time. Although the Company believes that its expectations and the information in this Presentation were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Presentation. The Company is not making any representation or warranty, expressed or implied, as to the accuracy, reliability, or completeness of the information in the Presentation, and neither the Company nor any of its directors, officers, or employees will have any liability to the reader or any other persons resulting from the reader's use of the information in the Presentation. The Company undertakes no obligation to publicly update or revise any forward-looking information or statements in the Presentation. The reader should consult any further disclosures the Company may make in documents it files with the applicable securities regulators.




OUR COMPANY




We build intelligent automation platforms that accelerate chemical process development, increase data quality, and reduce development costs.




**AUTOMATION &
ROBOTICS**



**ADVANCED
ANALYTICAL TECHNOLOGY**



**ARTIFICIAL
INTELLIGENCE**



**PROCESS
DEVELOPMENT**

TELI (CSE)
TELIF (OTCQB)

WHO WE ARE



Our award-winning scientific leadership includes a 2-time Nobel Prize Winner in Chemistry. We have collectively authored over 450 academic publications and 34 patents.



PROF. JASON HEIN
CTO AND DIRECTOR

Leads one of the largest academic chemistry research groups in Canada. Has authored 50+ peer-reviewed articles amassing over 4,000 citations. Directed the development of the DirectInject-LC platform that is the flagship product for Telescope



DR. BARRY SHARPLESS
SENIOR ADVISOR

2-time winner of the Nobel Prize in Chemistry. His work has been described as “the most important discovery in the field of synthesis during the past few decades”.



HENRY DUBINA
CEO AND CHAIRMAN

35+ years experience in General Management in the Scientific Instrument Industry. As President and Global Head of Mettler-Toledo AutoChem, he directed the development of the business from inception to the global market leader for enabling tools, software and services for biopharmaceutical and chemical process development.



DR. JEFF SHERMAN
COO

Over 30 years of experience with leading suppliers of lab technology including Micromeritics Instrument Corporation, ThermoFisher Scientific, and Mettler-Toledo.



JOHN KIRINCIC
CFO

20+ years of executive level experience in leading and growing companies through financial and operating functions. Deep corporate finance background working with growth-oriented companies in direct roles and through buy-side investment capital firms building value for shareholders.

OUR BOARD OF DIRECTORS



Our directors bring over 80 years combined experience in building technology companies and successfully managing companies in the capital markets.



DR. ANDY ROBINSON

An experienced scientist with a 20+ year successful track record in creating concepts, building companies and teams, and then taking them to successful execution. Andy has held executive and board positions with a range of public and private companies. He is the President, COO & Director of Standard Lithium, a company leveraging unique process chemistry to build the first American commercial lithium project in over 50 years.



ROBERT MINTAK

20+ years experience in corporate management in a wide range of private and public companies with a specific emphasis on strategic development, corporate governance, and long-term creation of shareholder value. As the CEO of Standard Lithium, he has led the company to its position among the 50 best performers on the OTCQX market.



ALI PEJMAN

20+ years experience as an Investment Banker having advised over \$25 Billion in M&A transactions and \$3 Billion in equity financings. He is currently Managing Partner at Fort Capital, a boutique investment bank. Pejman is an active angel investor and Associate of the Creative Destruction Labs, with current and prior Board positions on Science World, Vancouver Transit Police, and Vancouver/UBC General Hospital. He has been instrumental in large purposed fundraising for brain research and care.



PROF. JASON HEIN

At the University of British Columbia, Prof. Hein heads one of the largest academic chemistry research groups in Canada. He has authored over 50 peer-reviewed articles amassing over 4,000 citations on crystallization, purity, commercial scale-up and the role of automation, robotics and AI in controlling pharmaceutical production.



HENRY DUBINA

As the President and Head of Mettler-Toledo AutoChem for over 20 years, he directed the global business from Research & Development, Manufacturing, and Marketing, to Sales and Service. AutoChem instruments have been ubiquitously deployed in academia and industry for biopharmaceutical, chemical, and advanced materials applications to boost R&D productivity.

OUR VISION



1

International leadership in online chemistry sampling and analysis **products**



2

Provider-of-choice for **Self-Driving Laboratories**



3

Global deployment in chemical and pharmaceutical **process development**



OUR BUSINESS MODEL: TECHNOLOGY DEVELOPMENT



WORLD-CLASS SCIENTISTS



We've collectively authored over **450 academic publications** and **34 patents**.


R&D WITH STRATEGIC INDUSTRIAL CLIENTS



Our established IP & know-how is built into intelligent automation platforms. We accelerate chemical process development with **strategic clients and partners**.

New IP enriches our team and partnerships.

NEW MARKET-DRIVEN IP & KNOW-HOW



Analytical tools and methods
Chemistry automation workflows

Patent portfolios:

- Synthetic routes to key therapeutics
- Production of battery materials



PRODUCT DEVELOPMENT

Our products **fit clear unmet market needs**, and our industrial partnerships bolster product development.




aqualung



HATCH



OUR BUSINESS MODEL: REVENUE GENERATION



FLAGSHIP PRODUCT

A process analytical technology for automated analysis of chemical reactions

In first year of launch, units are deployed at 13 of the top 20 pharma companies in the world

"...automation, lab digitization, and data-rich experimentation aren't luxuries anymore; they are necessities..."

Jason Hein, CTO



DIRECTINJECT - LC™




GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET*




KEY DRIVERS

- Massive, increasing R&D spending in pharma and biotech
- Need for automation and quality control in pharmaceutical manufacturing

GLOBAL MARKET SIZE



2021 BREAKDOWN BY TECHNIQUE



*Data source: Infogence Global Research, Global Process Analytical Technology Market 2021-2027, published May 2021

STRONG INVESTMENTS IN SELF-DRIVING LABORATORIES (SDLs)



\$CAD 500 M | 2023

Acceleration Consortium

\$200 M: Largest Canadian federal research grant (CFREF)
+ \$300 M: Matching by industry & academic partners

 **MERCK | 2022**

Autonomous Process
Optimization Division



National Science
Foundation | **2023**

10-Year roadmap for SDL investment

SDLs combine
robotics and AI to
accelerate chemistry
& process
development by
10 - 100X

£ 81 M | 2018

Materials Innovation Factory

 **Pfizer | 2021**

Center for Digital Innovation
Manufacturing intelligence & automation

STRATEGIC PARTNERS AND CLIENTS



INSTRUMENTATION & TECHNOLOGY PARTNERS



PHARMACEUTICAL COMPANIES




ENGINEERING & MINING COMPANIES



GOVERNMENT AND ACADEMIA



CONFIDENTIAL DRAFT



Enabling Technologies
CONSORTIUM®



telescopeinnovations.com

BUILDING A SUCCESSFUL TRACK RECORD



TELI (CSE)

TELI (OTCQB)

Repeat clients for Self-Driving Labs in chemical and pharmaceutical manufacturing



Second **profitable** quarter closed (Q3, FY2023)

DIRECTINJECT - LC™ deployed by 13 of top 20 pharma companies in the world

Global distribution partnership for DIRECTINJECT - LC™



Telescope closes its first **profitable** quarter (Q2, FY2023)

Telescope is granted a **Canadian** patent on chemical synthesis route

2 provisional patents filed on chemical manufacturing



Product launch
DIRECTINJECT - LC™

Telescope is hired by **aqualung**

Accelerator funding received for new chemical manufacturing technology



New partnership to develop automation product



Product development partnership (DirectInject-LC™)




KEY BUSINESS PLAN ELEMENTS FOR 2024 AND 2025



SAMPLING / ANALYSIS PRODUCTS

SELF-DRIVING LABORATORIES

CHEMICAL / PHARMA PROCESS DEVELOPMENT



2024

Global distribution of **DIRECTINJECT - LC** via market-leading vendor: [METTLER TOLEDO](#)

Complete development of 2 new products: **DIRECTINJECT - MS** and **DIRECTINJECT - IC**

Formalize consortium of key pharma companies to fund development

Complete development of Phase 1 of the SDL platform

Maintain and expand process research & development client services

Build business plan and skills to support service franchise

2025

Release of **DIRECTINJECT - MS** and **DIRECTINJECT - IC** through global distribution channel

Complete development of **DIRECTINJECT - ICP** and **DIRECTINJECT - NMR**


Develop SDL platform to initial commercial platform

Implement IP licensing business

STRONG GROWTH IN FIRST 2 YEARS

- Revenue-positive in first full fiscal year (FY 2022)
- 375% increase in revenue from FY 2022 to FY 2023
- Major development in FY 2024: Global Distribution Agreement signed with Market-leading vendor (Mettler Toledo AutoChem) for DirectInject-LC™

All values expressed in CAD.
Complete financial statements available on SEDAR
(www.sedar.com).



CAPITALIZATION



STOCK TICKER SYMBOLS TELI (CSE), TELIF(OTCQB)

CAPITAL STRUCTURE December 2023	PRICE Average	NUMBER
Shares issued		53,665,569
Stock options	\$ 0.54	4,283,050
Warrants	\$ 0.75	2,439,749
Fully Diluted Share Position		60,388,749

Shares held by Directors / Officers - 12,866,650 (24%)



THANK YOU

Contact:
investors@telescopeinn.com